This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bovie Medical Corporation Announces First Quarter Financial Results; Revenues Increase 10% Over Previous Year

Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter and year ended March 31, 2011.

Revenues for the first quarter ended March 31, 2011 increased 10% to $6.2 million versus $5.6 million for the comparable period last year. Revenues were positively impacted by increased OEM generator sales as well as higher electrosurgical disposable sales.

Net income was $492,000 or $.03 per diluted share compared to a loss of ($226,000) or ($.01) per share in the same period last year. During the quarter, the Company received a one-time payment of $750,000 as part of a previously announced settlement of a legal action with Salient Surgical Technologies, Inc. and Medtronic, Inc. This gain was reflected in our results of operations as a gain from settlement of litigation.

Andrew Makrides, chief executive officer of Bovie Medical, stated, “Both new and longstanding OEM customer sales increases positively impacted on first quarter revenues. We are pleased with the revenue gains and the trend continued early into the second quarter. We are also encouraged by the response that our network of independent sales representatives is receiving from surgeons and buyers of medical equipment throughout the country.”

Mr. Makrides continued, “Due to the much longer process of clearing new products through the Food & Drug Administration, we have dedicated additional resources both internal and external to the application process. The application phase for J-Plasma™ continues as we await 510k clearance. The company also expects to file a re-submission of its vessel sealing product during the second or third quarter.”



In the first quarter, Bovie Medical increased J-Plasma’s exposure to the medical community by meeting with and gaining support and input from physicians, nurses and physician assistants in specialties such as Gynecology, Uro-gynecology and Plastic Surgery, as well as sub-specialties such as robotic surgery. As a result of recent testing and industry trade shows, we believe Bovie will be better positioned to market J-Plasma in foreign markets earlier than previously anticipated, although the initial focus continues to be for the U.S. market. We intend to continue studies beyond the current 510k filing of the J-Plasma device to establish further uses of the technology and expand its revenue potential.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.61 -0.70%
FB $100.97 -0.03%
GOOG $680.34 -0.55%
TSLA $152.55 6.20%
YHOO $26.56 -2.00%


Chart of I:DJI
DOW 15,647.96 -266.78 -1.68%
S&P 500 1,835.31 -16.55 -0.89%
NASDAQ 4,275.63 -7.9620 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs